Skip to main navigation Skip to search Skip to main content

Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia

  • Jakub Zieg*
  • , Anna Krepelova
  • , Alireza Baradaran-Heravi
  • , Elena Levtchenko
  • , Encarna Guillén-Navarro
  • , Miroslava Balascakova
  • , Martina Sukova
  • , Tomas Seeman
  • , Jiri Dusek
  • , Nadezda Simankova
  • , Tomas Rosik
  • , Sylva Skalova
  • , Jan Lebl
  • , Cornelius F. Boerkoel
  • *Corresponding author for this work
  • Charles University
  • University of British Columbia
  • KU Leuven
  • Hospital Virgen de la Arrixaca

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Autoimmunity is often observed among individuals with primary immune deficiencies; however, the frequency and role of autoimmunity in Schimke immuno-osseous dysplasia (SIOD) has not been fully assessed. SIOD, which is caused by mutations of SMARCAL1, is a rare autosomal recessive disease with its prominent features being skeletal dysplasia, T cell deficiency, and renal failure. We present a child with severe SIOD who developed rituximab resistant Evans syndrome (ES). Consistent with observations in several other immunodeficiency disorders, a review of SIOD patients showed that approximately a fifth of SIOD patients have some features of autoimmune disease. To our best knowledge this case represents the first patient with SIOD and rituximab resistant ES and the first study of autoimmune disease in SIOD.

Original languageEnglish
Article number27
JournalPediatric Rheumatology
Volume9
DOIs
Publication statusPublished - 13 Sept 2011
Externally publishedYes

Keywords

  • Evans Syndrome
  • Nephrotic Syndrome
  • Osseous Dysplasia
  • Rituximab
  • Schimke Immuno
  • Unilateral Renal Agenesis

Fingerprint

Dive into the research topics of 'Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia'. Together they form a unique fingerprint.

Cite this